Kornimate/medical-research-clean huggingface dataset:
biomarker discovery in parkinson's disease

Conditions: Parkinson's Disease

Summary: there are approximately one million americans who live with parkinson's disease with 50,000 new cases per year and this rate is expected to rise with an aging population. the underlying pathophysiology and disease understanding of pd still remains elusive due to a combination of disease complexity and lack of predictive capability of existing models. the berg interrogative biology™ discovery platform has demonstrated a unique capability in producing drug targets and biomarkers that truly represent a disease phenotype. it has been able to catalyze molecules now in late stage clinical trials in cancer and many pre-clinical candidate therapeutics and biomarkers in endocrinology and central nervous system (cns) diseases. the platform is able to decipher normal versus disease signatures by integration of data sets from the genome, metabolome, proteome, and lipidome in an agnostic manner that is subjected to bayesian artificial intelligence informatics. the resulting nodes are then put back into wet-lab validation before proceeding to proof-of-principle pre-clinical testing. by utilizing clinical data and specimens obtained by the medical specialists at the parkinson's institute, along with berg's interrogative biology™, this study aims to discover a disease biomarker enabling the creation of a diagnostic test for parkinson's disease.


Eligibility criteria:
inclusion criteria: for pd cases: inclusion criteria: * men and women with the clinical diagnosis of idiopathic pd * willing and able to give informed consent * willing and able to comply with scheduled visits, required study procedures and laboratory tests exclusion criteria: pd subjects with any of the following may not be enrolled: 1. presence of atypical or secondary parkinsonism 2. inability to provide a blood and/or urine sample 3. history of renal failure and/or on dialysis 4. currently taking a medication in the following categories: dopamine blockers, neuroleptics, and/or dopamine blocking agents. 5. any medical, psychiatric or other condition which, in the opinion of the investigator, would preclude participation healthy controls: all of the following criteria must be met for a healthy control to be enrolled in the study: 1. healthy controls with no diagnosis of pd and any of the exclusion criteria 2. willing and able to give informed consent 3. willing and able to comply with scheduled visits, required study procedures and laboratory tests healthy controls with any of the following may not be enrolled: 1. no clinically significant or unstable medical or psychiatric condition that would interfere with the conduct of the study 2. diagnosis of pd or presence of signs of a neurodegenerative disorder, e.g. essential tremor 3. first degree relative with pd/parkinsonism 4. inability to provide a blood and/or urine sample 5. history of renal failure and/or on dialysis 6. any medical, psychiatric or other condition which, in the opinion of the investigator, would preclude participation

Keywords: parkinson's disease biomarkers blood urine, proteomics lipidomics metabolomics
long-term outcome of zonal outer retinopathy in punctate inner choroidopathy or multifocal choroiditis

Conditions: Punctate Inner Choroidopathy

Summary: to report the long term prognosis in patients with punctate inner choroidopathy (pic) or multifocal choroiditis (mfc) and associated zonal outer retinopathy (zor).


Eligibility criteria:
inclusion criteria: * patients with punctate inner choroidopathy (pic) or multifocal choroiditis (mfc) and associated zonal outer retinopathy (zor). * follow up over 4 years. exclusion criteria: * patients with punctate inner choroidopathy (pic) or multifocal choroiditis (mfc) without zonal outer retinopathy (zor).

Keywords: punctate inner choroidopathy multifocal choroiditis zonal outer retinopathy long-term outcome
efficacy of soluble beta-1,3/1,6-glucan compared to placebo on chronic leg ulcers in diabetes patients

Conditions: Foot Ulcer

Summary: the purpose of this study is to evaluate the efficacy of soluble beta-1,3/1,6-glucan compared to placebo on the healing of chronic leg ulcers in diabetes patients. hypothesis: through its ability to activate tissue macrophages and counteract diabetes-associated defects in macrophages, the soluble beta-1,3/1,6-glucan will promote the healing of leg ulcers in diabetic patients.

diabetes predisposes to ulceration of the foot through a variety of processes, including neuropathy and peripheral arterial disease. once the skin is broken, healing is frequently delayed and the ulcer develops the biology of a chronic wound. the factors underlaying delayed healing in chronic wounds are not well understood but include the effects of repeated trauma, tissue ischemia, infection, defective white cell function, altered immune processes, and altered expression of tissue cytokines and enzymes. management is based on regular cleansing and debridement, off-loading and treatment of intercurrent infection with antibiotics. there are no interventions in routine use, which target aspects of chronic wound biology directly.

Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes mellitus * age\>= 18 years * study wound is a wagner grade 1 partial thickness or grade 2 full thickness lesion but without exposed tendon, joint, or bones * study wound located on the foot or lower leg * study wound must have been present for at least 4 weeks prior to day 0 but not longer than 2 years * adequate circulation to the foot, evidenced by a palpable pulse on the study foot * study wound \> 1.0cm2 but \< 20.0cm2 * written informed consent exclusion criteria: * pregnancy, lactation or absence of adequate contraception for fertile women * ankle/brachial index \< 0.7 * severe malnutrition * clinical evidence of gangrene on any part of the foot with the study wound * active or extensive cellulitis extending more than 1 cm beyond wound margin and/or presence of cellulitis with purulent discharge on day 0 * one or more medical condition(s) that in the opinion of the investigator would make the patient an inappropriate candidate for the study * active osteomyelitis of the foot with the study wound * necrotic toes on the foot with the study wound * surgical procedure (other than debridement) on the foot with the study wound the last 21 days prior to screening * study wound over a charcot's joint * evidence of deep tissue infection of the study wound at day 0 * non-study wound on the study foot that is located within 5.0cm from the study wound at day 0 * random blood sugar reading \> 450 mg/dl * alcohol or drug abuse * participation in other clinical studies in the last 4 weeks
a research study looking at a new study medicine (nnc0194-0499) for weight control in people with overweight or obesity

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this study looks at a new study medicine for weight control in people with overweight or obesity. the aim of this study is to see if the study medicine is safe for people to take. the study also looks at how fast the body removes the study medicine. the participants will either get nnc0194-0499 (the study medicine) or placebo (a formula that looks like the medicine but does not have active ingredients). which treatment the participants get is decided by chance. the participants will get 1 or more injections into the skin of stomach area once each week for 12 weeks. the study will last for about 4 to 5 months. the participants will have 18 visits to the clinic.


Eligibility criteria:
inclusion criteria: * male aged 22-55 years (both inclusive) or female aged 22-45 years (both inclusive) at the time of signing informed consent * female must have regular menstrual cycle(defined as 24-35 days between 1st day of menses for two most recent menstrual periods, self-reported) * female must have bilateral tubal ligation or must be willing to use non-hormonal intrauterine device or diaphragm /cervical cap with spermicide in combination with condom for male partner(s) * body mass index (bmi) between 27.0 and 39.9 kg/sqm (both inclusive). overweight should be due to excess adipose tissue, as judged by the investigator * considered by the investigator to be generally healthy based on the medical history, physical examination, and the results of vital signs, ecg, and clinical laboratory tests performed during the screening visit exclusion criteria: * any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol * use of prescription or non-prescription medicinal products including herbal products and non-routine vitamins, within 2 weeks prior to screening. mild painkillers are allowed until 24 hours prior to screening * history or presence of bone disease or otherwise increased risk of bone fracture as evaluated by dual-energy x-ray absorptiometry and as judged by the investigator
chronic obstructive pulmonary disease (copd) co-pilot air substudy of cln0014

Conditions: COPD Symptoms After Coil Procedure

Summary: the purpose of undertaking cln0020, which was a substudy of the european coil registry (cln0014), was to investigate the use of copd co-pilot air™, a copd disease management program manufactured and operated by hge health care solutions, llc, in participants undergoing the pneumrx endobronchial coil treatment in a post-market setting.

copd co-pilot air™ combines a digital respiratory symptom reporting participant application (an "app") with facilitation of rapid personalized clinical recommendations made by the participant's health care provider and communicated to the participant through the application. copd co-pilot air™ provides early identification of an increase in a participant's respiratory symptoms relative to the participant's own baseline symptom profile which in turn enables health care providers to rapidly implement modified treatment plans.

Eligibility criteria:
inclusion criteria: 1. participant has read, understood, and signed a cln0020 informed consent form prior to enrollment. 2. participant is appropriate for coil treatment per the conformité européene (european conformity \[ce\])-mark approved repneu instructions for use (ifu). 3. participant has been enrolled in and scheduled for treatment(s) with the pneumrx endobronchial coil procedure in the cln0014 study. 4. participant's pneumrx endobronchial coil procedure is scheduled to occur no fewer than 14 days from enrollment, providing enough time to establish a baseline of their daily symptoms. ten days minimum of baseline data are required, which is defined as the run-in period going forward. 5. participant is willing and able to use a smart phone. exclusion criteria: 1. participant has undergone a coil procedure. 2. participant has had an acute exacerbation of copd that required hospitalization or emergency room visit or treatment with systemic steroids and/or antibiotics during the 28 days prior to cln0020 enrollment. 3. participant has a copd exacerbation or respiratory illness during the run-in period that in the judgment of the investigator requires medical intervention (for example, treatment with systemic steroids and/or antibiotics and/or hospitalization). 4. participant is suffering from terminal illness expected to adversely affect survival in the next 12 months. 5. participant has a history of non-compliance with medical therapies.

Keywords: copd coils app
long-term, substantial weight loss and insulin regulation of lipolysis

Conditions: Obesity, Morbid

Summary: it is not known how much improvement in insulin regulated lipolysis (the breakdown of triglycerides) occurs following substantial, sustained weight loss. researchers will test the effects of inflammation and lipolysis regulation in people before and after bariatric surgery (sleeve gastrectomy) to answer these questions.

the purpose of this study is to determine whether the adipose inflammatory cell and cytokine content in class iii obesity is related to lipolysis insulin resistance and, if so, whether sustained, substantial weight loss one year following bariatric surgery reduces inflammation in parallel with improved insulin regulation of lipolysis

Eligibility criteria:
inclusion criteria: * bmi 40 - 50 kg/m2. * mo active physical illness that would interfere with mobility or weight loss after bariatric surgery exclusion criteria: * type 1 or type 2 diabetes diagnosis or fasting plasma glucose ≥126 mg/dl * active coronary artery disease * participation in structured exercise (\>2 times per week for 30 minutes or longer) * smoking * medications known to affect adipose tissue metabolism (e.g., beta blockers, corticosteroids) * renal insufficiency (serum creatinine \> 1.5mg/dl) * chronic active liver disease (bilirubin \> 17mmol/l, ast \> 144 iu/l, or alt\>165iu/l) * pregnancy or breastfeeding.
remifentanil requirement in patients receiving surgical treatment of parkinson's disease

Conditions: Parkinson's Disease

Summary: parkinson's disease (pd) is one the main neurodegenerative disease with an incidence of about 3% in patients older than 65 years. anesthesia in pd patients has been focused by several studies for concerning the interactive reaction between anesthetics and anti-parkinsonian medication or parkinsonian symptoms. however, our previous experience showed that the patients undergoing pulse generator placement were more prone to be involved in delayed emergence in the recovery room, which had been not reported yet. we speculated that pd patients might be a special population with abnormal pharmacodynamic characters of anesthetics, though no related evidence could be found to support this hypothesis. therefore, in this project we investigated whether remifentanl requirement to inhibit patients' response to trachea intubation and skin insertion in pd patients undergoing dbs and pulse generator placement was different from non-pd patients undergoing intracranial surgery for reasons other than pd.


Eligibility criteria:
inclusion criteria: * adult parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement * adult non-parkinsonian patients undergoing intracranial surgery exclusion criteria: * asa score higher than class ii * predicted difficult airway * alcohol or drug abuser * informed consent was not provided

Keywords: parkinson's disease remifentanil deep brain stimulator cardiovascular response
philips intracardiac echocardiography (ice) clinical registry

Conditions: Atrial Fibrillation; Stroke; Valve Disease, Heart; Atrial Septal Defect; Patent Foramen Ovale; Mitral Valve Disease; Tricuspid Valve Disease; Aortic Valve Disease

Summary: the purpose of this observational registry is to report real-world safety and performance of verisight for ultrasound guided ice imaging in percutaneous cardiac intervention procedures when used in standard clinical practice.

this is a prospective, multi-center, observational, single-arm registry intended to gather real-world data to report verisight ice catheter performance and safety. it will be conducted in the united states under the approval of one or more recognized institutional review boards and in compliance with good clinical practice guidelines defined in international standards organization:14155;2011, the declaration of helsinki, and all applicable federal and local laws and regulations. only on label uses of the verisight ice catheter will be allowed. no specific claims are being validated during this registry, though data analyzed from this protocol are intended to inform of future claims regarding the performance and safety of the verisight catheter. enrolled patients will be imaged with verisight for various types of percutaneous cardiac interventional procedures. enrolled subjects will be followed until discharge or ≤48 hrs post-procedure. the registry has a planned duration of approximately 24-36 months with interim analysis planned at 100 patients before further enrollment will be considered. statistical hypotheses are not intended for this registry and descriptive analysis will be conducted. data from all clinical sites are intended to be pooled for analysis. it is possible that sub-analyses may be conducted to demonstrate verisight guidance for target intervention types in structural heart and electrophysiology procedures.

Eligibility criteria:
inclusion criteria: 1. 18 years of age and willing to provide written, dated and signed, informed consent 2. scheduled for a procedure that is within the scope of clinical indication for verisight per instructions for use (ifu) exclusion criteria: 1. contraindicated for ice catheter placement or patient considerations that make placement of verisight not technically feasible 2. if alternate access (as needed instead of femoral) is not viable 3. known contraindicated conditions include sepsis, major coagulation abnormalities, presence of any intracardiac thrombus, presence of class iv angina or heart failure, deep vein thrombosis, or significant peripheral vascular disease.

Keywords: ice image guided therapy structural heart electrophysiology intracardiac echocardiography atrial fibrillation stroke ablation valve disease
the effects of muscle characteristics on the control of shoulder complex during functional movements

Conditions: Other Instability of Joint, Shoulder Region; Strain of Shoulder Muscle (Disorder); Movement Disorders

Summary: the movement control of shoulder joint relies not only on the glenohumeral joint, but also the critical contributions from scapulothoracic joint. the relating scapula muscle strength, scapula mobility and, the most important of all, the capacity of neuromuscular control should be integrated into the rehabilitation program for patients with shoulder disorders. with regarding to the subacromial impingement syndrome or rotator tendinopathy, the status of scapula dyskinesia and dysfunctions were improved significantly after the intervention of scapula-emphasized exercise. but there was no study addressed the relationships between stiffness of relating muscles and the deficits of scapula movement. the stiffness had been shown to serve an important role in functional performance of the corresponding joint. for example, the decreased elasticity of supraspinatus muscle was noticed on affected side comparing in patients with impingement syndrome.few studies examined the effects of altered muscle stiffness on kinematic performance in shoulder complex. laudner et al. found that the stiffer the latismuss dorsi muscle was, the less upward rotation and posterior tilting, and the more internal rotation of scapula during arm elevation was exhibited in asymptomatic swimmers. another study showed that the increased range of external rotation and posterior tilt of scapula during arm elevation were associated with the decreased stiffness of pectoralis minor. the recent study presented that the electromyographic activities and elasticities of middle deltoid, supraspinatus, and infraspinatus muscles correlated significantly with the tissue elasticity during shoulder movement in healthy shoulder. however, there was no scientific information directly to prove the changes in characteristics of rotator cuff function as well as the impacts on kinematic control of shoulder complex. therefore, the aim of this study is to examine the relationship among characteristics of muscle properties and kinematic control healthy swimmers.


Eligibility criteria:
inclusion criteria: * freestyle swimmers with health shoulders exclusion criteria: * the past or current shoulder pain or disorders are examined by history taking and screening tests: shoulder impingement syndrome, instability, bony deformity, trauma, nerve injury or entrapment.

Keywords: scapula dyskinesia muscle stiffness scapulohumeral rhythm electromyography
capsaicin for the treatment of cannabinoid hyperemesis syndrome

Conditions: Cannabinoid Hyperemesis Syndrome

Summary: this study aims to determine if capsaicin cream offers symptomatic relief to patients suffering from cannabinoid hyperemesis syndrome (condition that leads to repeated and severe bouts of vomiting).

objectives: the purpose of this study is to determine if capsaicin cream offers symptomatic relief to patients suffering from cannabinoid hyperemesis syndrome. we hypothesize that the use of topical capsaicin may provide effective symptomatic relief more quickly than conventional anti-emetic therapy alone thereby decreasing costs for continued drug therapies, repeat laboratory testing, radiographic imaging, and specialist consults. primary endpoint: time to resolution of symptoms, clinical improvement in pain score as defined by visual analog score. approach and methods: patients presenting to the uva emergency department with chief complaint of nausea and vomiting who endorse cannabinoid use via inhalation or consumption. patients 18 years of age and older will be included in the study and patients who have another clear indication for nausea/vomiting or cyclic vomiting (infection, appendicitis, pain, etc.) will be excluded. patients who are enrolled in the study will be randomized 1:1 to treatment vs. placebo. all patients will be allowed 1l of intravenous fluids and one to two standard anti-emetics. the investigational drug services team at uva will be involved in compounding the capsaicin treatment versus placebo and drug/placebo shall remain in place for at least 30 minutes. clinical improvement will be scored based on visual analog score for pain and assessment at hourly increments until discharge or admission.

Eligibility criteria:
inclusion criteria: * at least 18 years old * diagnosis of cannabinoid hyperemesis syndrome exclusion criteria: * patients who receive more than 2 anti-emetic therapies prior to screening for enrollment * patients who receive haloperidol as an anti-emetic therapy * pregnant women * prisoners
an intervention targeting daily adaptive skills through executive function training for adults with asd

Conditions: Autism Spectrum Disorder; High-functioning Autism; Autism

Summary: the current study is a single group pilot study of a novel intervention program which targets improvements in executive functions and adaptive skills in transition age young adults with high-functioning autism spectrum disorder. the main aim of the study is to test the effectiveness of the intervention using a pretest-posttest comparison. it is hypothesised that there will be an increase in executive functions and adaptive skills after the intervention.

the participants engaged in a 10-week group-based intervention program which aims to improve daily adaptive skills based on executive functions and help the transition into adulthood in young adults with asd. before and after the intervention, the participants and their parents completed questionnaires that measure executive functions and adaptive skills, and the participants additionally completed an assessment of social adaptive skills. the differences between pre- and post-intervention scores of the outcome measures were analyzed using wilcoxon signed-rank tests to evaluate the effect of the program.

Eligibility criteria:
inclusion criteria: * a clinical diagnosis of asd as measured by the autism diagnostic observation schedule and the autism diagnostic interview-revised * full-scale iq of 70 or above as measured by the weschler adult intelligence scale exclusion criteria: * full-scale iq less than 70 * uncooperative and lacking motivation to participate in the programme * reporting clinically significant behavioural problems, emotion regulation problems, psychotic symptoms, risk of self-harm or harm to others which can affect the participation to the programme, which is screened by the screening assessments and interviews.

Keywords: autism spectrum disorder high-functioning autism autism executive function intervention